Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Preferred Stock Liabilities (2019)

Historic Preferred Stock Liabilities for Vivos Therapeutics (VVOS) over the last 1 years, with Q4 2019 value amounting to $1.3 million.

  • Vivos Therapeutics' Preferred Stock Liabilities changed N/A to $1.3 million in Q4 2019 from the same period last year, while for Dec 2019 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2019, which is N/A changed from last year.
  • Vivos Therapeutics' Preferred Stock Liabilities amounted to $1.3 million in Q4 2019.
  • Vivos Therapeutics' Preferred Stock Liabilities' 5-year high stood at $1.3 million during Q4 2019, with a 5-year trough of $1.3 million in Q4 2019.